Clodronic acid: Difference between revisions
Can't comment about analgesic effects from an in-vitro study |
|||
(28 intermediate revisions by 23 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{unreferenced|date=November 2014}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
|||
| verifiedrevid = 476996903 |
| verifiedrevid = 476996903 |
||
⚫ | |||
| image = Clodronic acid.png |
| image = Clodronic acid.png |
||
| alt = |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|international|clodronic-acid}} |
| Drugs.com = {{drugs.com|international|clodronic-acid}} |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
⚫ | |||
| pregnancy_US = <!-- A / B / C / D / X --> |
|||
⚫ | |||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> |
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> |
||
| legal_CA = Rx-only |
|||
| legal_CA_comment = |
|||
| legal_UK = <!-- GSL / P / POM / CD --> |
| legal_UK = <!-- GSL / P / POM / CD --> |
||
| legal_US = <!-- OTC / Rx-only --> |
| legal_US = <!-- OTC / Rx-only --> |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 10596-23-3 |
| CAS_number = 10596-23-3 |
||
⚫ | |||
⚫ | |||
| PubChem = 25419 |
| PubChem = 25419 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
Line 30: | Line 35: | ||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 12318 |
| ChEMBL = 12318 |
||
<!--Chemical data--> |
<!--Chemical data--> |
||
⚫ | |||
| C=1 | H=4 | Cl=2 | O=6 | P=2 |
| C=1 | H=4 | Cl=2 | O=6 | P=2 |
||
| molecular_weight = 244.892 g/mol |
|||
| smiles = ClC(Cl)(P(=O)(O)O)P(=O)(O)O |
| smiles = ClC(Cl)(P(=O)(O)O)P(=O)(O)O |
||
| InChI = 1/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) |
|||
| InChIKey = ACSIXWWBWUQEHA-UHFFFAOYAO |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) |
| StdInChI = 1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) |
||
Line 42: | Line 46: | ||
}} |
}} |
||
'''Clodronic acid''' ([[International Nonproprietary Name|INN]]) or '''clodronate disodium''' ([[United States Adopted Name|USAN]]) is a first generation (non-nitrogenous) [[bisphosphonate]]. It is an anti-osteoporotic drug |
'''Clodronic acid''' ([[International Nonproprietary Name|INN]]) or '''clodronate disodium''' (Na<sub>2</sub>CH<sub>2</sub>Cl<sub>2</sub>O<sub>6</sub>P<sub>2</sub>) ([[United States Adopted Name|USAN]]) is a first generation (non-nitrogenous) [[bisphosphonate]]. It is an anti-osteoporotic drug approved for the prevention and treatment of [[osteoporosis]] in post-menopausal women and men to reduce vertebral fractures, [[hyperparathyroidism]], [[hypercalcemia]] in malignancy, [[multiple myeloma]] and fracture related pain because of its anti-inflammatory effects shown as a reduction in inflammatory markers like [[Interleukin 1 beta|IL-1β]], [[Interleukin 6|IL-6]], and [[Tumor necrosis factor alpha|TNF-α]].<ref>{{cite journal | vauthors = Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J | title = Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro | journal = Pharmaceutical Research | volume = 12 | issue = 6 | pages = 916–22 | date = June 1995 | pmid = 7667201 | doi = 10.1023/A:1016281608773 | s2cid = 46332840 }}</ref> |
||
== Medical uses == |
|||
An Italian study compared the analgesic effect of clodronic acid versus [[acetaminophen]] in rheumatic condition related pain. Study result show a reduction in pain in favor of clodronic acid that provided more analgesia than 3 grams/day of acetaminophen. Clodronate is also used in experimental medicine to selectively deplete [[macrophages]]. |
|||
A study comparing the analgesic effect of clodronic acid versus [[acetaminophen]] in osteoporotic vertebral fractures showed that clodronic acid provided more analgesia than 3 grams/day of acetaminophen.<ref>{{cite journal | vauthors = Rovetta G, Monteforte P, Balestra V | title = Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture | journal = Drugs Under Experimental and Clinical Research | volume = 26 | issue = 1 | pages = 25–30 | date = 2000 | pmid = 10761534 | doi = }}</ref> |
|||
Clodronic acid is also used in experimental medicine to selectively deplete [[macrophages]]. |
|||
⚫ | |||
⚫ | Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent. It is not approved for use in the United States, because it has too many adverse effects. |
||
==Use in equine medicine== |
|||
⚫ | Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of |
||
==Veterinary uses== |
|||
===Adverse reactions and contraindications=== |
|||
⚫ | Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of [[navicular syndrome]]. It is given by intramuscular injection at one point in time, with the total dose divided into 2-3 sites on the horse. Clinical effects (e.g. improvement of lameness) after a single treatment can be seen up to 6 months post-treatment. |
||
⚫ | |||
=== Adverse effects === |
|||
⚫ | Clodronic acid has been shown to have several adverse effects. These include:<ref>{{cite web|last1=U.S. Food and Drug Administration.|title=FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular Syndrome in Horses|website=[[Food and Drug Administration]] |url=https://www.fda.gov/AnimalVeterinary/ResourcesforYou/ucm406581.htm|access-date=3 January 2015}}</ref> |
||
* Signs of discomfort, agitation, or [[horse colic|colic]], usually within 2 hours of treatment. |
* Signs of discomfort, agitation, or [[horse colic|colic]], usually within 2 hours of treatment. |
||
* Head shaking |
* Head shaking |
||
* Lip licking |
* Lip licking |
||
* [[acute kidney injury|Renal failure]] |
|||
⚫ | |||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
⚫ | |||
{{Portal bar|Chemistry}} |
|||
[[Category:Bisphosphonates]] |
[[Category:Bisphosphonates]] |
||
[[Category:Equine medications]] |
[[Category:Equine medications]] |
||
[[Category:Organochlorides]] |
|||
{{musculoskeletal-drug-stub}} |
Latest revision as of 14:50, 17 November 2023
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.031.090 |
Chemical and physical data | |
Formula | CH4Cl2O6P2 |
Molar mass | 244.88 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Clodronic acid (INN) or clodronate disodium (Na2CH2Cl2O6P2) (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its anti-inflammatory effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-α.[1]
Medical uses
[edit]A study comparing the analgesic effect of clodronic acid versus acetaminophen in osteoporotic vertebral fractures showed that clodronic acid provided more analgesia than 3 grams/day of acetaminophen.[2]
Clodronic acid is also used in experimental medicine to selectively deplete macrophages.
Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent. It is not approved for use in the United States, because it has too many adverse effects.
Veterinary uses
[edit]Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of navicular syndrome. It is given by intramuscular injection at one point in time, with the total dose divided into 2-3 sites on the horse. Clinical effects (e.g. improvement of lameness) after a single treatment can be seen up to 6 months post-treatment.
Adverse effects
[edit]Clodronic acid has been shown to have several adverse effects. These include:[3]
- Signs of discomfort, agitation, or colic, usually within 2 hours of treatment.
- Head shaking
- Lip licking
- Renal failure
References
[edit]- ^ Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J (June 1995). "Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro". Pharmaceutical Research. 12 (6): 916–22. doi:10.1023/A:1016281608773. PMID 7667201. S2CID 46332840.
- ^ Rovetta G, Monteforte P, Balestra V (2000). "Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture". Drugs Under Experimental and Clinical Research. 26 (1): 25–30. PMID 10761534.
- ^ U.S. Food and Drug Administration. "FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular Syndrome in Horses". Food and Drug Administration. Retrieved 3 January 2015.